Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $1.91 in the prior trading day, Inovio Pharmaceuticals Inc (NASDAQ: INO) closed at $1.96, up 2.62%. In other words, the price has increased by $2.62 from its previous closing price. On the day, 2.28 million shares were traded. INO stock price reached its highest trading level at $2.05 during the session, while it also had its lowest trading level at $1.9.
Ratios:
Our goal is to gain a better understanding of INO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.66 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on July 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $5.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $20.
Oppenheimer Upgraded its Perform to Outperform on January 25, 2024, while the target price for the stock was maintained at $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INO now has a Market Capitalization of 104159696 and an Enterprise Value of 67268384. For the stock, the TTM Price-to-Sale (P/S) ratio is 578.64 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 368.923 whereas that against EBITDA is -0.713.
Stock Price History:
The Beta on a monthly basis for INO is 1.56, which has changed by -0.73866665 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, INO has reached a high of $7.76, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is 17.82%, while the 200-Day Moving Average is calculated to be -12.26%.
Shares Statistics:
The stock has traded on average 1.92M shares per day over the past 3-months and 2814170 shares per day over the last 10 days, according to various share statistics. A total of 53.14M shares are outstanding, with a floating share count of 52.72M. Insiders hold about 0.79% of the company’s shares, while institutions hold 19.15% stake in the company. Shares short for INO as of 1753920000 were 5096499 with a Short Ratio of 2.65, compared to 1751241600 on 5500739. Therefore, it implies a Short% of Shares Outstanding of 5096499 and a Short% of Float of 10.05.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Inovio Pharmaceuticals Inc (INO).The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.41 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.88 and -$2.31 for the fiscal current year, implying an average EPS of -$2.05. EPS for the following year is -$1.7, with 5.0 analysts recommending between -$1.33 and -$1.95.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for INO’s current fiscal year. The highest revenue estimate was $100k, while the lowest revenue estimate was $65k, resulting in an average revenue estimate of $88.33k. In the same quarter a year ago, actual revenue was $217.76kBased on 6 analysts’ estimates, the company’s revenue will be $14.14M in the next fiscal year. The high estimate is $41.5M and the low estimate is $1.05M.
